
Alpine Immune Sciences Investor Relations Material
Latest events

Study Update
Alpine Immune Sciences
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Alpine Immune Sciences Inc
Access all reports
Alpine Immune Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for autoimmune and inflammatory diseases, as well as cancer. The company uses its proprietary platform to engineer protein-based therapies that modulate the immune system to enhance treatment efficacy. Alpine's approach aims to create novel immunotherapies that target immune pathways, offering potential treatments for patients with unmet medical needs in areas such as immuno-oncology and autoimmune disorders. Its pipeline includes a range of drug candidates designed to address these conditions. The company is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
ALPN
Country
🇺🇸 United States